Five Prime Therapeutics Inc. (FPRX)

18.34
NASDAQ : Health Technology
Prev Close 18.75
Day Low/High 18.30 / 19.11
52 Wk Low/High 17.05 / 49.30
Avg Volume 535.30K
Exchange NASDAQ
Shares Outstanding 34.01M
Market Cap 637.03M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Underwriters Fully Exercise Option to Purchase Additional Shares

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells

First Week of February 16th Options Trading For Five Prime Therapeutics (FPRX)

Investors in Five Prime Therapeutics, Inc saw new options become available this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

Commit To Purchase Five Prime Therapeutics At $17.50, Earn 21% Annualized Using Options

Investors considering a purchase of Five Prime Therapeutics, Inc shares, but tentative about paying the going market price of $22.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $17.50 strike, which has a bid at the time of this writing of $1.65.

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b Antibody In Greater China And Global Strategic Development Collaboration

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b Antibody In Greater China And Global Strategic Development Collaboration

Planned global Phase 3 FIGHT trial in front-line gastric and gastro-esophageal junction cancers to include sites in China where disease incidence is the highest in the world

Five Prime Therapeutics is Now Oversold (FPRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics To Host Conference Call On November 8 To Review Cabiralizumab Phase 1a/1b Data

Five Prime Therapeutics To Host Conference Call On November 8 To Review Cabiralizumab Phase 1a/1b Data

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that it will host a...

Five Prime Therapeutics is Now Oversold (FPRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

First Week of November 17th Options Trading For Five Prime Therapeutics (FPRX)

Investors in Five Prime Therapeutics, Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D (Sell)